StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN)

Equities research analysts at StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN) in a research report issued on Thursday. The brokerage set a “sell” rating on the stock.

Oragenics Trading Down 3.9 %

Shares of NYSE:OGEN opened at $0.29 on Thursday. The company has a market cap of $3.57 million, a price-to-earnings ratio of -0.04 and a beta of 0.49. The company has a 50-day moving average price of $0.35 and a 200-day moving average price of $0.98. Oragenics has a 12 month low of $0.25 and a 12 month high of $7.74.

Hedge Funds Weigh In On Oragenics

A hedge fund recently bought a new stake in Oragenics stock. Virtu Financial LLC purchased a new position in Oragenics, Inc. (NYSE:OGEN) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned approximately 0.51% of Oragenics at the end of the most recent reporting period. Institutional investors own 18.71% of the company’s stock.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.